CARs in the Fast Lane? Universal Allogeneic Therapy Moving Forward

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Commercially available CAR-T products such as Yescarta and Kymriah have shown the power of cell therapies to eradicate deadly cancers even after several failed lines of treatment. While early cell therapies offer new hope, they rely on patient-derived cells and access to these cells is limited. This panel will review the potential advantages of readily available off-the-shelf cell therapy products and discuss what’s required to make them a reality.
Moderator
photo
Shareholder
Wolf Greenfield
Speakers
photo
Chief Scientific Officer
Precision Biosciences
photo
Moffitt Cancer Center
photo
Shareholder
Wolf Greenfield